Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Prostate cancer explained: PSA testing, risk and treatment choices

    About 13.2% of US men, roughly one in eight, will be diagnosed with prostate cancer; SEER publishes American Cancer Society projections of about 333,830 new cases and 36,320 deaths in 2026.[1] Most cases are found while still localized, and 5-year relative survival, based on SEER data for 2016–2022, is 98.2% overall.[2] The USPSTF says PSA screening at ages 55 to 69 should be an individual decision; it calls the potential benefit small for some men, while many experience harms such as false positives and overtreatment.[3][4]

    Editor reviewedStrict sourcingUpdated Explainer15 claims · 100% primaryHealth and medicine
    Reading level: 1 passage differs; the rest is the same for everyone.

    This page is general information, not medical advice. Talk to a clinician about urinary symptoms and about whether PSA testing makes sense for you.

    The prostate is a walnut-sized gland in the male reproductive system. It sits below the bladder and in front of the rectum, and makes fluid that is part of semen.[5] About 13.2% of US men, roughly one in eight, will be diagnosed with it. SEER publishes American Cancer Society projections of about 333,830 new cases and 36,320 deaths in 2026.[1]

    Most prostate cancers are found early. About 69% are localized at diagnosis, and SEER reports 5-year relative survival, based on 2016–2022 data, of 98.2% overall. When the cancer has spread to distant sites, survival is 40.1%.[2] Incidence rose about 2.7% a year over 2014-2023, while death rates fell about 0.8% a year over 2015-2024.[6]

    Who is at risk

    Prostate cancer is most common in older men. NCI says men at higher risk include Black men, carriers of inherited BRCA2 variants (and, to a lesser extent, BRCA1), and men whose father or brother had prostate cancer.[7]

    Symptoms

    Possible signs include trouble starting urination, frequent urination (especially at night), trouble emptying the bladder and a weak or interrupted flow. Other conditions can cause the same symptoms, including a prostate that enlarges with age.[8]

    The PSA test and the screening debate

    Prostate cancer can raise the level of PSA in the blood, but so can benign conditions such as an enlarged prostate (BPH) and inflammation (prostatitis). In general, a level above 4.0 ng/mL is considered abnormal and may lead to a recommendation for a biopsy.[9]

    NCI says about 6% to 7% of men have a false-positive PSA test in any screening round. Only about 25% of men biopsied because of an elevated PSA turn out to have prostate cancer.[10] Screening can also cause overdiagnosis, which means finding tumours that would never have caused problems in a man’s lifetime. Treating those tumours is overtreatment.[11]

    The USPSTF‘s May 2018 recommendation says PSA screening for men aged 55 to 69 should be an individual decision (grade C). It recommends against screening from age 70 (grade D), and an update is in progress.[3] The task force calls the potential benefit small for some men, while many experience harms such as false positives, biopsies, overdiagnosis and overtreatment.[4] In May 2026 the UK National Screening Committee recommended against population screening. It backed a PSA test every 2 years only for men aged 45 to 61 who carry a harmful BRCA2 variant and have a relevant family history.[12] The cancer screening explainer compares prostate screening with the other programmes.

    Diagnosis and treatment choices

    A biopsy gives the cancer a Gleason score. NCI calls a score of 6 low grade, 7 medium grade and 8 to 10 high grade. Higher scores mean the cancer is more likely to grow and spread quickly.[13]

    Treatment does not always start straight away. Active surveillance follows the cancer with tests such as PSA, exams and biopsies, and starts curative treatment if it begins to grow. Watchful waiting gives treatment only to relieve symptoms when they appear or change.[14]

    When treatment is needed, NCI lists surgery, radiation and radiopharmaceutical therapy, hormone therapy, chemotherapy, targeted therapy and immunotherapy. Targeted options include PARP inhibitors such as olaparib for cancer that has spread and carries BRCA mutations. Radiation therapy can cause impotence and urinary problems.[15]

    More in this series: colorectal cancer, lung cancer, breast cancer and skin cancer. For other health topics, see the health crash course.

    US Preventive Services Task Force (USPSTF)

    The USPSTF sets the US cancer screening recommendations that shape free coverage. How it grades evidence, what it recommends, and its 2026 overhaul.

    Developing in Health

    Go deeper

    Questions readers ask

    Should I get a PSA test?

    The USPSTF says PSA screening for men aged 55 to 69 should be an individual decision, and recommends against it from age 70. In the UK, the National Screening Committee recommended screening only a small high-risk group of men with a BRCA2 variant and a family history.[3][12]

    Does a high PSA mean I have cancer?

    No. Benign conditions such as an enlarged prostate (BPH) and prostatitis can also raise PSA. NCI says only about 25% of men biopsied because of an elevated PSA are found to have prostate cancer.[9][10]

    Who is at higher risk of prostate cancer?

    Prostate cancer is most common in older men. NCI lists Black men, men with inherited BRCA2 (and to a lesser extent BRCA1) variants, and men whose father or brother had prostate cancer as being at higher risk.[7]

    What is active surveillance?

    Active surveillance means following the cancer closely with tests such as PSA and biopsies, without treatment unless results change, and giving curative treatment if it begins to grow. Watchful waiting gives treatment only to relieve symptoms.[14]

    What does a Gleason score mean?

    It is a grade from a biopsy. NCI says 6 is low grade, 7 medium grade and 8 to 10 high grade, and higher scores mean the cancer is more likely to grow and spread quickly.[13]

    Sources

    · 15 claims from 5 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      SEER publishes ACS projections of about 333,830 new US prostate cancer cases and 36,320 deaths in 2026; about 13.2% of men, roughly one in eight, will be diagnosed in their lifetime. confirmedas of 2026-11-07

    2. [2]

      SEER reports 5-year relative survival, based on SEER 21 data for 2016-2022, for prostate cancer of 98.2% overall and 40.1% when distant; about 69% of cases are found at the localized stage. confirmedas of 2026-11-07

    3. [3]

      The USPSTF (May 2018) says PSA screening for men aged 55 to 69 should be an individual decision (grade C) and recommends against it at 70 and older (grade D); an update is in progress. confirmedas of 2026-10-11

    4. [4]

      The USPSTF says PSA screening offers a small potential benefit for some men, while many experience harms such as false positives, biopsies, overdiagnosis and overtreatment. confirmedas of 2026-10-11

    5. [5]

      The prostate is a walnut-sized gland in the male reproductive system, below the bladder and in front of the rectum, that makes fluid that is part of semen. confirmedas of 2026-11-07

    6. [7]

      Prostate cancer is most common in older men; men at higher risk include Black men, carriers of inherited BRCA2 (and to a lesser extent BRCA1) variants, and men whose father or brother had prostate cancer. confirmedas of 2026-11-07

    7. [8]

      Possible prostate cancer signs include trouble starting urination, frequent urination especially at night, trouble emptying the bladder and a weak or interrupted flow; other conditions, including a prostate that enlarges with age, can cause the same symptoms. confirmedas of 2026-11-07

    8. [9]

      PSA levels can rise because of prostate cancer or benign conditions such as benign prostatic hyperplasia (BPH) and prostatitis; a level above 4.0 ng/mL is generally considered abnormal and may lead to a biopsy recommendation. confirmedas of 2026-11-07

    9. [10]

      NCI says about 6% to 7% of men have a false-positive PSA test in any screening round, and only about 25% of men biopsied because of an elevated PSA are found to have prostate cancer. confirmedas of 2026-11-07

    10. [11]

      NCI defines overdiagnosis as detecting tumours that would not have caused problems in a person's lifetime, and overtreatment as treating them. confirmedas of 2026-11-07

    11. [12]

      In May 2026 the UK NSC recommended targeted prostate screening, with a PSA test every 2 years, for men aged 45 to 61 who carry a harmful BRCA2 variant and have a family history of breast, ovarian, pancreatic or prostate cancer, and recommended against population screening. confirmedas of 2026-05-28

    12. [13]

      A biopsy gives prostate cancer a Gleason score; a score of 6 is low grade, 7 medium grade and 8 to 10 high grade, and higher scores mean the cancer is more likely to grow and spread quickly. confirmedas of 2026-11-07

    13. [14]

      Active surveillance follows prostate cancer with tests such as PSA and biopsies and gives curative treatment if it begins to grow, while watchful waiting gives treatment only to relieve symptoms when they appear or change. confirmedas of 2026-11-07

    14. [15]

      Prostate cancer treatments listed by NCI include surgery, radiation and radiopharmaceutical therapy, hormone therapy, chemotherapy, targeted therapy (including PARP inhibitors for spread cancer with BRCA mutations) and immunotherapy; radiation can cause impotence and urinary problems. confirmedas of 2026-11-07

    Revision history (2)
    1. Stated that SEER survival figures are based on 2016–2022 data.
    2. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 7, 2027.

    Cite this page

    "Prostate cancer explained: PSA testing, risk and treatment choices." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/prostate-cancer-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.